Ab Science SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AB Science SA initiates phase 3 study of masitinib in combination with docetaxel
AB Science SA:Announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with docetaxel in first line treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC).Says this international, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC).Says the study will measure overall survival as a primary efficacy criterion.Says the phase 3 study has been authorized by competent authorities and will recruit 550 patients.
Latest Developments forAb Science SA
- AB Science's Mastinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA
- AB Science SA announces positive phase 2 clinical study of Masitinib
- AB Science SA announced the successful completion of futility test for masitinib in Alzheimer
- AB Science SA announces positive phase 2 clinical study data of masitinib in second-line metastatic stomach cancer
- Share this
- Digg this